About Synairgen Synairgen is a clinical-stage respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic. Synairgen is currently fully focused on progressing its inhaled interferon beta1a broad spectrum antiviral drug as an effective treatment for people suffering with COVID-19 infection. Synairgen s differentiating human biology BioBank platform and world-renowned international academic KOL network has broader applicability for lung viral defence in other respiratory disorders including asthma and COPD. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com COVID-19 COVID-19, caused by the SARS-CoV-2 virus, is a global threat and there is an urgent need to assess new treatments to prevent and effectively treat the severe lower respiratory tract illness that can occur with this disease. Older people
PRESS RELEASE
Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine
Agreement provides a framework for future clinical trials, manufacturing, sales and marketing, and distribution within the National Health Service of Brazil
Bio-Manguinhos, is a world leader in vaccine development and manufacturing and one of the productive units of Fiocruz, one of the world s most respected public health research institutions
Abingdon, Oxon, UK, 5 January 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of synthetic ‘set point’ vaccines which prime the T-Cell immune response, today announces that it has signed a collaboration and development agreement with the Institute of Technology on Immunobiologicals (Bio-Manguinhos) of the Oswaldo Cruz Foundation (Fiocruz) in Brazil to develop a COVID-19 vaccine usi
News Category Global Banking & Finance Reviews
Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine
PRESS RELEASE
Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine
Agreement provides a framework for future clinical trials, manufacturing, sales and marketing, and distribution within the National Health Service of Brazil
Bio-Manguinhos, is a world leader in vaccine development and manufacturing and one of the productive units of Fiocruz, one of the world’s most respected public health research institutions
Abingdon, Oxon, UK, 5 January 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of synthetic ‘set point’ vaccines which prime the T-Cell immune response, today announces that it has signed a collaboration an
Synairgen plc: COVID-19 Clinical Programme Update
Phase III trial design adapted which will expedite results
Phase III trial to commence dosing in UK imminently
Southampton, UK - 18 December 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces updates to the Company s Phase III trial design evaluating SNG001 as a treatment for patients with COVID-19 and positive progress on the regulatory path.
Update to Phase III trial (SG018) protocol in COVID-19 patients
Following discussions with the regulatory agencies, the trial has been amended as follows:
Removal of the lower dose arm, thereby reducing the number of patients required to complete the placebo-controlled trial from 900 patients to 610 patients
COVID-19 Clinical Programme Update – IT Business Net itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.